Aprogen pharmaceuticals,Inc. Overview
Aprogen Biologics is a loss-making, majority-controlled Korean pharmaceutical and biologics manufacturer. It combines a 65-year-old domestic ethical-drug business, inherited from Kunpoong and Schnell, with one of Korea's largest perfusion-based antibody plants in Osong. Group materials put the plant's investment at about KRW 600 bn and its capacity at roughly 3,000 kg of antibody a year. Within the Aprogen group, the company is the designated manufacturer for biosimilars and novel biologics developed by its parent, Aprogen Inc. These include the infliximab biosimilar GS071, the trastuzumab biosimilar AP063, and the adalimumab and rituximab candidates AP096 and AP056. In Q1 2026, however, Osong recorded zero litres of biologic output, and the company has posted operating losses of KRW 52.8–60.4 bn a year since FY2023. A newly reported semiconductor segment is currently its only profitable division. The investment case rests on AP063 approvals following FDA and EMA regulatory feedback that waives Phase 3, on the first commercial CDMO contracts, and on how long the parent can continue funding the company.
What the company does
Aprogen Biologics operates three reportable activities, plus residual "other" items.
-
Pharmaceutical business (제약사업부문). This is the legacy Kunpoong/Schnell business: manufacture and domestic sale of prescription and generic medicines. Third-party profiles describe the line-up as including amino-acid infusion products and antibiotics (Dealroom). Asia Economy (June 2020) described the predecessor, Aprogen Pharmaceuticals, as an antibiotics-focused drug maker. Recruitment postings (Catch, 2026) refer to a Hwaseong plant with a tablet-coating production line, a regulatory-affairs (RA) development team, and a "CSO support team." The CSO reference indicates the company uses contract sales organisations for domestic marketing. In Q2 2026 the segment generated 62% of revenue (Butler).
-
Bio business (바이오사업부문). This is the Osong cGMP biologics plant acquired through the December 2022 merger with the former unlisted Aprogen Biologics. The plant was completed in January 2020. It holds the following capacity:
-
Drug substance: four 2,500 L bioreactors (2,000 L working volume) and two 250 L bioreactors, designed for perfusion culture.
-
Drug product: fill-finish lines for lyophilised vials, liquid vials, prefilled syringes and auto-injectors. The segment's intended revenue streams are (a) manufacturing the Aprogen group's biosimilars and (b) third-party CMO/CDMO work. In Q2 2026 the segment contributed only 3% of revenue (Butler) and generated nearly all of the operating loss: about KRW 13.2 bn in Q1 2026 and about KRW 30.5 bn in H1 2026 (IB Tomato).
-
-
Semiconductor business (반도체사업부문). This segment appears in 2026 segment reporting. It contributed 33% of Q2 2026 revenue and an operating profit of about KRW 2.25 bn in H1 2026 (Butler; IB Tomato). Its origin, legal form and products could not be confirmed in sources reviewed. Elsewhere in the group, semiconductor-equipment parts are made by N2Tech (엔투텍, vacuum gate valves), which group-level profiles associate with Aprogen Inc. (Valueline).
Business and revenue model
| Revenue stream | Type | Status (2026) |
|---|---|---|
| Domestic prescription / generic drugs | Product sales | Core revenue; segment profitable in Q1 2026 (KRW 1.8 bn operating profit), loss-making in H1 2026 (about –KRW 3.3 bn) |
| Biosimilar manufacturing for the Aprogen group | Contract manufacturing / intra-group supply | No commercial output in Q1 2026 (0 L produced) |
| Third-party CMO/CDMO | Service | Trial fill-finish run for a "Company C" completed (Hankyung, January 2025); audits by a European "Company O"; no commercial contract confirmed in sources reviewed |
| Semiconductor products | Product sales | 33% of Q2 2026 revenue; only profitable segment in H1 2026 |
| Related-party services | Service | Aprogen Inc. recorded about KRW 1.9 bn of service transactions with the company between March and August 2026 (IB Tomato) |
Licensing income does not appear to be booked at Aprogen Biologics. Biosimilar IP and out-licensing rights sit with Aprogen Inc. Partner Nichi-Iko paid upfront fees of KRW 10 bn each for GS071, AP063 and AP056 to Aprogen, not to the listed predecessor (Medical Times, March 2016). Under the 2020 group restructuring plan, the listed predecessor held domestic biosimilar sales rights. Asia Economy also reported that a profit-allocation agreement on production from the Osong facility was planned. Its current terms are not publicly disclosed.
Value-chain position, customers and end-markets
Value-chain position: Downstream manufacturer within a vertically split group. In the 2020 design, Aprogen Inc. does R&D, the listed predecessor does sales, and Aprogen Biologics does production. After the December 2022 merger, the listed entity carries both the sales (pharma) and production (bio) roles.
Customers: - Pharma: hospitals, clinics and pharmacies in Korea, served directly and through CSOs and distributors.
-
Bio: Aprogen Inc. (captive) and prospective third-party biopharma CDMO clients in Korea, Japan and Europe.
-
Semiconductor: not disclosed.
End-markets: Korean prescription-drug market; global biosimilar supply (indirectly, through Aprogen's partners such as Nichi-Iko in Japan); global biologics CDMO; semiconductor supply chain (details undisclosed).
Company self-description vs. independent characterisation
The company's English-language self-description in its latest annual report was not accessible in sources reviewed. Group investor materials (Aprogen IR, June 2025) present Osong as a facility with globally unmatched manufacturing cost. They state that a single 2,500 L perfusion bioreactor batch (about 200 kg before purification for AP096) equals the output of four to six 15,000 L fed-batch bioreactors at competitors. The group targets a "Global Top Tier CDMO" position and expected a turnaround around 2027.
Independent characterisation. Aprogen Biologics is a sub-scale domestic generic-drug company carrying a large, idle biologics asset. Its losses are structural. Fixed costs at Osong, including about KRW 3.1 bn of quarterly depreciation on KRW 152.8 bn of machinery (Q1 2026), are not covered by output, and the plant's utilisation depends on regulatory milestones of the parent's biosimilars. Since 2024 the company has relied on related-party funding: placements to the parent, convertible bonds bought by affiliates, and parent loans. It has also pledged its own core real estate as collateral for the parent's borrowings. The semiconductor segment adds diversification but has no stated strategic link to the biologics business.
Strategy
Stated strategy (group investor materials, June 2025; paraphrased)
The group describes its ambition as becoming a company with world-class commercial competitiveness from R&D through manufacturing. It identifies four vectors:
-
Accelerate biosimilar development and approvals.
-
Co-develop or out-license new-drug projects.
-
Open global sales channels.
-
Fully launch the CDMO business.
The group also claims a cost advantage: perfusion culture combined with high-yield cell lines would let it set prices well below those of fed-batch competitors.
Three business pillars and 13 projects (Aprogen IR, June 2025)
| Pillar | Projects | Status claimed (Jun 2025) |
|---|---|---|
| Biosimilar CDMO (contract development and manufacturing) | 6 | 1 molecule contracted (DS and DP); 3 under negotiation; bispecific manufacturing platform; out-licensing of an acute-leukaemia ADC antibody |
| Biosimilar licensing (rights) business | 3 | AP063 Phase 3; AP096 and AP056 clinical material completed |
| Novel biologics | 4 | 1 molecule preclinical completed (AP209); 2 in preclinical; 1 in optimisation |
The group expected a turnaround around 2027.
Initiatives in the last 24 months
| Initiative | Date | Description | Measurable target |
|---|---|---|---|
| CDMO commercialisation drive | 2024–2025 | Dedicated Japan and Europe CDMO sales organisation; marketing at BIO-Europe and BIO International; Biosecure Act positioning | First commercial contract expected "within 1–2 months" as of January 2025; not confirmed |
| Osong expansion design | By Jan 2025 | Production building designed for 1.5× capacity | Construction conditional on customer demand |
| AP063 regulatory pivot | Nov 2025–May 2026 | Global Phase 3 redesigned to quality and comparative-PK focus; FDA pre-BLA feedback that Phase 3 is not required | About KRW 130 bn development-cost saving (Aprogen claim); BLA after PPQ |
| Balance-sheet repair | 2024–2026 | 10:1 consolidation (2024) and 15:1 capital reduction (2026) to cover accumulated deficit; avoid KRX penny-stock delisting rules | Keep price above KRW 1,000 and market cap above the KOSPI threshold |
| Unspecified acquisition | Sep 2026 | KRW 20 bn raised for acquiring securities of an undetermined company | No target named |
| Treasury deployment | Sep 2026 | KRW 29.1 bn one-year loan to 아인스팩 at 4.6% | Not stated |
ESG or sustainability commitments, and cost programmes with numeric targets: none publicly disclosed in sources reviewed.
Medium-term financial guidance: none issued by Aprogen Biologics. In 2020 the group projected revenue above KRW 1 trillion by 2026 (Asia Economy, Apr 2020). Actual group revenue in FY2025 was KRW 118.0 bn at the parent level.
Products & Services
Bio segment — Osong manufacturing services
| Offering | Description / specifications | Target customer | Year | Pricing |
|---|---|---|---|---|
| Drug-substance manufacturing (perfusion) | 4 × 2,500 L (2,000 L working) and 2 × 250 L (200 L working) bioreactors; 4 purification lines. Group states about 125,000 L harvested per batch, about 2.8 million L of culture fluid per year, and 3,000 kg of antibody per year | Aprogen group; third-party biopharma | Plant completed Jan 2020 | — |
| Drug-substance manufacturing (fed-batch mode) | Same bioreactors operated fed-batch; about 300,000 L of culture fluid per year (Asia Economy, Mar 2023) | Third-party CDMO clients using conventional processes | Available since 2020 | — |
| Drug product: lyophilised vials | IMA Life equipment; 6.4 million vials per year (Aprogen IR, Jun 2025) | Group and third parties | 2,020 | — |
| Drug product: liquid vials | Bosch equipment. Capacity stated as 60 million vials per year (Aprogen IR, Jun 2025) but 15 million per year in March 2023 company statements (Asia Economy); the discrepancy is unresolved | Group and third parties | 2,020 | — |
| Drug product: prefilled syringes | Optima equipment; 80 million PFS per year | Group and third parties | 2,020 | — |
| Auto-injector assembly and secondary packaging | Auto-injector assembler, labellers, cartoner, case packer, palletiser | Group and third parties | 2,020 | — |
| Warehousing and QC support | Automated warehouse (720 cells at 2–8°C; 2,040 cells at 15–25°C); 2 LN2 tanks for cell banks (18,200 × 2 ml vials each); 7 deep freezers; SCADA, LIMS, EDMS, EMS/BMS systems | Group and third parties | 2,020 | — |
Bio segment — products manufactured (or to be manufactured) for the Aprogen group
| Product | Reference product / indication | Status (latest) | Osong role |
|---|---|---|---|
| GS071 | Remicade (infliximab) biosimilar; autoimmune disease | Approved in Japan (2017), marketed there through Nichi-Iko; US Phase 3 completed 2019–2020; global rights licensed to Nichi-Iko (2014) | Commercial batch production began 2021 |
| AP063 | Herceptin (trastuzumab) biosimilar; HER2+ breast cancer | Global Phase 3 started 2023 (19 countries, 720 patients) and later terminated early or redesigned. EMA scientific advice and FDA pre-BLA feedback (8 May 2026) indicate approval may proceed without confirmatory Phase 3. PPQ batches are the next step. | Clinical supply produced; PPQ and commercial supply planned. Group claims 92 kg per batch and 736 kg per year (8 batches), equal to about 40% of global consumption |
| AP096 | Humira (adalimumab) biosimilar; arthritis and Crohn's | Clinical material produced (pre-approval run in November 2024 harvested 201.5 kg HCCF); preparing for clinic | Group claims 156 kg per batch and 1,248 kg per year |
| AP056 | Rituxan (rituximab) biosimilar; haematological cancers and autoimmune disease | Clinical material production completed (IR, Jun 2025); ex-Korea rights licensed to Nichi-Iko (2016) | Group claims 102 kg per batch and 714 kg per year |
| AP209 | Dual-receptor-Fc fusion protein; osteoarthritis | Korean clinical trial approved for 46 patients (2026); IRB filing at Kyung Hee University Hospital (August 2026) | Clinical drug substance produced at Osong |
| Parkinson's candidate ("substance K") | Neurodegeneration; co-development with Prof. Chung Jong-kyung (Seoul National University) | Preclinical; 3 patents in-licensed | Osong to manufacture clinical drug (Hankyung, Jan 2025) |
These assets are developed and owned by Aprogen Inc. Aprogen Biologics' role is manufacturing, and historically, domestic distribution rights.
Note: IB Tomato (May 2026) described GS071 as a rituximab biosimilar and AP056 as a trastuzumab biosimilar. That conflicts with the company's own investor materials, which identify GS071 as infliximab, AP063 as trastuzumab and AP056 as rituximab.
Pharmaceutical segment
| Product line | Description | Target customer | Notes |
|---|---|---|---|
| Amino-acid infusion products | Parenteral nutrition | Hospitals | Third-party description (Dealroom); brand names not disclosed in sources reviewed |
| Antibiotics | Anti-infectives | Hospitals and clinics | Asia Economy (Jun 2020) described the company as antibiotic-focused; brands not disclosed |
| Oral solid dosage generics | Coated tablets made at the Hwaseong plant | Clinics and pharmacies | Inferred from recruitment postings (Catch, 2026); product names not disclosed |
| Historical portfolio (Kunpoong era) | Injectables, IV fluids, syrups, oral solids | Domestic | eToday (Feb 2010) |
| Raloxifene (COVID-19 repurposing study, 2020) | Investigator-led trial at Ajou University Medical Center | — | — |
Product-level revenue, pricing and launch years for pharmaceutical products are not publicly disclosed in sources reviewed.
Semiconductor segment
Products, customers and specifications are not publicly disclosed in sources reviewed.
Financial Narrative
Income statement (consolidated, DART basis via Butler)
Sources: Butler (revenue, operating income, net income FY2021–FY2025). Margins and growth rates are calculated from those figures. Butler reports FY2025 growth as +8.7% and the operating-loss change as –14.3%, based on unrounded figures.
Revenue CAGR FY2021–FY2025: about 6.7% a year (KRW 56.5 bn to KRW 73.2 bn, calculated).
Additional data points:
-
H1 2026: revenue KRW 44.7 bn; operating loss KRW 31.1 bn (IB Tomato, Sep 2026).
-
TTM to mid-2026: revenue about KRW 86.2 bn; EBITDA about –KRW 39.4 bn (MarketInOut, Sep 2026).
-
TTM EPS: –KRW 5,853 (Investing.com, on a post-consolidation share basis) and –KRW 5,872 (MarketInOut).
-
Dividends: none currently (Paasa). The accumulated deficit (–KRW 413.9 bn at Q1 2026) rules out legal dividend capacity.
Commentary.
FY2021–FY2022 (pre-merger): The listed company was a small domestic drug maker. Revenue was KRW 56.5–65.2 bn and operating losses were modest (KRW 3.8–5.4 bn). Net income was positive (KRW 9.2 bn and KRW 5.6 bn), so non-operating gains must have exceeded operating losses. The nature of those gains (for example, valuation gains or interest income) is not disclosed in sources reviewed.
FY2023 (first full year with Osong): Revenue rose 34.0% to KRW 87.4 bn, but the operating loss grew roughly tenfold to KRW 57.5 bn (Asia Economy, Mar 2024). Asia Economy attributed the persistent loss to fixed costs, including SG&A, that revenue could not absorb. The net loss of KRW 115.3 bn implies about KRW 58 bn of non-operating charges (interest, CB-related valuation and/or impairments; breakdown not disclosed).
FY2024: Revenue fell 22.9% to KRW 67.4 bn. The reasons are not disclosed in sources reviewed. Contributing factors could include intra-group supply timing or pharma volumes. The operating loss narrowed slightly to KRW 52.8 bn, and the net loss was KRW 105.0 bn.
FY2025: Revenue recovered 8.6% to KRW 73.2 bn, but the operating loss widened to KRW 60.4 bn. The net loss rose to KRW 168.3 bn, the largest in the five-year window. The roughly KRW 108 bn gap between operating and net loss points to heavy financial or other expenses. Likely components are CB interest and derivative valuation, impairments, or losses on related-party investments; the breakdown is not publicly disclosed in sources reviewed.
2026 run-rate: The H1 2026 operating loss (KRW 31.1 bn) annualises to about KRW 62 bn, so FY2023–FY2025 loss levels are continuing. The bio segment accounts for virtually all of the loss.
Balance sheet (point-in-time data; full 5-year series not publicly accessible in sources reviewed)
Sources: Hankyung (Jan 2024) for September 2023; Aprogen IR (Jun 2025) for March 2025 total assets; IB Tomato (May 2026) for Q1 2026.
Cash and equivalents, gross debt by maturity, net debt, goodwill and intangibles, and working capital for FY2021–FY2025 are not publicly disclosed in sources reviewed. MarketInOut reports debt-to-equity of 1.09 (September 2026).
Commentary.
Equity erosion: Equity roughly halved from KRW 541.4 bn (September 2023) to KRW 272.8 bn (Q1 2026), despite more than KRW 100 bn of new equity raised in 2024.
Deficit relief: The 2026 capital reduction converted about KRW 92.6 bn of share capital into deficit relief, a book entry that does not affect total equity.
Impairment risk: The large machinery balance (KRW 152.8 bn) on a plant that produced nothing in Q1 2026 creates material impairment risk under K-IFRS 1036, as IB Tomato noted.
Encumbered assets: About KRW 81 bn of collateral has been pledged over Osong real estate for the parent's debts. This reduces the company's own borrowing capacity and creates contingent exposure to the parent's credit.
Cash flow
Operating cash flow, capex, free cash flow, dividends paid and buybacks for FY2021–FY2025 are not publicly disclosed in sources reviewed. Funding activity, however, shows the company has depended on external financing:
The 18th-series CB was raised to repay the 17th-series CB issued in March 2025.
Uses of funds:
2024 offering: debt repayment (KRW 30.9 bn of the planned amount), Osong operating costs and equipment upgrades, PPQ test production for AP063 and AP096, and repayment of parent loans (Hankyung; Asia Economy).
September 2026 placement: "acquisition of securities of another company," with counterparty, target and price basis all left undetermined at filing.
September 2026 loan: the company lent KRW 29.1 bn to 아인스팩 for one year at 4.6%. It described the loan as strategic fund management for financial-structure improvement (Dealsite, 23 Sep 2026).
Ratios (latest available; aggregator TTM data)
Current ratio, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle cannot be computed from verified data and are not publicly disclosed in sources reviewed. Net debt/EBITDA and interest coverage are economically meaningless given negative EBITDA.
Parent context: Aprogen Inc. (007460) consolidated, which includes Aprogen Biologics
Sources: Aprogen IR (June 2025) for FY2021–FY2024; IB Tomato (Sep 2026) for FY2025 revenue and operating loss.
The parent's own persistent losses limit how long it can keep funding the subsidiary. The parent itself issued a KRW 20 bn CB in September 2026 to fund its subscription to Aprogen Biologics' placement.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Revenue
| Segment | Contents | Products / services | Q2 2026 revenue share (%) | Q1 2026 operating income (KRW Bn) | H1 2026 operating income (KRW Bn) |
|---|---|---|---|---|---|
Pharmaceuticals (제약사업부문) | Legacy Kunpoong/Schnell business; Hwaseong plant | Prescription and generic drugs, reportedly including amino-acid infusions and antibiotics | 62 | 1.8 | -3.3 |
Bio (바이오사업부문) | Osong cGMP biologics plant | Biosimilar drug substance and drug product manufacturing; CMO/CDMO | 3 | -13.2 | -30.5 |
Semiconductor (반도체사업부문) | — | — | 33 | — | 2.25 |
Other | — | — | 1 | — | — |
Total company | — | — | 100 | -13.6 | -31.1 |
“—” = not publicly disclosed.
Segment revenue (KRW Bn)
| Segment revenue (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total company | 87.4 | 67.4 | 73.2 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 56.5 | 65.2 | 87.4 | 67.4 | 73.2 |
Revenue growth YoY (%) | — | 15.4 | 34.0 | -22.9 | 8.6 |
Operating income (KRW Bn) | -3.8 | -5.4 | -57.5 | -52.8 | -60.4 |
Operating margin (%) | -6.7 | -8.3 | -65.8 | -78.3 | -82.5 |
Net income (KRW Bn) | 9.2 | 5.6 | -115.3 | -105.0 | -168.3 |
Net margin (%) | 16.3 | 8.6 | -131.9 | -155.8 | -229.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | Sep2023 | Mar2025 | Mar2026 |
|---|---|---|---|
Total assets (KRW Bn) | 744.9 | 581.3 | — |
Total equity (KRW Bn) | 541.4 | — | 272.8 |
Accumulated deficit (KRW Bn) | — | — | -413.9 |
Machinery and equipment, book value (KRW Bn) | — | — | 152.8 |
Capital and debt item
| Capital and debt item | Value (KRW Bn) | Date | Source |
|---|---|---|---|
Share capital before 2026 reduction | 99.2 | Feb 2026 | Dealsite |
Share capital after 15:1 reduction | 6.6 | Apr 2026 | Dealsite |
Convertible bonds outstanding (16th–18th series) | 115.0 | Oct 2025 | Dealsite |
19th-series CB issued | 10.0 | May 2026 | IB Tomato |
Loan payable to Aprogen Inc. | 53.5 | Early 2024 | Asia Economy (Mar 2024) |
Aprogen Inc. CB holdings in the company | 60.0 | Sep 2023 | Hankyung (Jan 2024) |
AP Healthcare finance-lease receivable from the company | 19.4 | Q2 2024 | NewDaily (Sep 2024) |
Collateral pledged for parent's borrowings (Osong land and buildings) | 81.0 | Jun 2026 | IB Tomato (9.0 Dec 2025 + 63.0 Apr 2026 + 9.0 Jun 2026) |
Financing Event Details
| Financing event | Date | Amount (KRW Bn) | Counterparty |
|---|---|---|---|
Rights offering (shareholder allotment plus public offering of unsubscribed shares) | Aug 2019 | 85.7 | Public / shareholders |
Rights offering (planned; resized from 117.2) | Mar–May 2024 | 72.4 | Shareholders; Korea Investment & Securities as underwriter |
Third-party placement | Jul 2024 | 60.0 | Aprogen Inc. |
16th-series CB (private) | Jul 2024 | 40.0 | — |
17th-series CB | Mar 2025 | 65.0 | — |
18th-series CB (3% coupon, matures 24 Oct 2030, conversion price KRW 605 pre-consolidation) | Oct 2025 | 15.0 | APTN (affiliate) |
Third-party placement | Apr 2026 | 2.0 | Aprogen Inc. |
19th-series CB | May 2026 | 10.0 | Aprogen Inc. |
Third-party placement | Jul 2026 | 2.0 | Aprogen Inc. |
Third-party placement (12,706,481 shares at KRW 1,574) | Sep 2026 | 20.0 | Aprogen Inc. |
“—” = not publicly disclosed.
Financial Analysis
| Ratio | Value | Date / source |
|---|---|---|
ROE (%) | -35.04 | Sep 2026, MarketInOut |
ROE (%) | -40.3 | Oct 2026, Butler |
ROE (%) | -50.55 | Aug 2026, StockHub |
ROA (%) | -13.43 | Sep 2026, MarketInOut |
ROIC (%) | -7.36 | Sep 2026, MarketInOut |
Pre-tax margin (%) | -85 | Sep 2026, MarketInOut |
Debt / equity (x) | 1.09 | Sep 2026, MarketInOut |
Altman Z-score | -1.19 | Sep 2026, MarketInOut |
Piotroski F-score | 4 of 9 | Sep 2026, MarketInOut |
Beneish M-score | -2.5 | Sep 2026, MarketInOut |
Price / book (x) | 0.22 | Oct 2026, Butler |
Balance Sheet (FY2021–FY2025)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 26.3 | 78.3 | 150.6 | 150.1 | 118.0 |
Gross profit (KRW Bn) | -0.4 | 6.2 | 35.8 | 34.9 | — |
Operating income (KRW Bn) | -94.6 | -119.3 | -88.9 | -86.8 | -95.6 |
Pre-tax income (KRW Bn) | -119.3 | -115.6 | -95.2 | -98.7 | — |
Net income (KRW Bn) | -119.2 | -116.1 | -97.3 | -100.4 | — |
Total assets (KRW Bn) | 477.6 | 599.9 | 594.4 | 609.9 | — |
Cash and equivalents (KRW Bn) | 15.9 | 43.1 | 35.7 | 37.1 | — |
Borrowings (KRW Bn) | 429.7 | 81.0 | 101.0 | 100.3 | — |
Net debt (KRW Bn) | 413.8 | 37.9 | 65.3 | 63.1 | — |
Total equity (KRW Bn) | -0.8 | 461.0 | 417.7 | 440.1 | — |
Region revenue (KRW Bn)
| Region revenue (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total | 87.4 | 67.4 | 73.2 |
Share Price & Returns
| Period | Return (%) | As-of date / source |
|---|---|---|
1 week | -4.42 | 9 Sep 2026, MarketInOut |
1 month | -21.46 | 9 Sep 2026, MarketInOut |
6 months | -76.62 | 9 Sep 2026, MarketInOut |
1 year | -81.55 | 9 Sep 2026, MarketInOut |
Year-to-date | -51.5 | 15 May 2026, SK Securities (Quantiwise) |
1 year | -62.2 | 15 May 2026, SK Securities (Quantiwise) |
3 years / 5 years | — | Not computed in sources reviewed; complicated by 2024 and 2026 consolidations |
Share Count (millions)
| Metric | Jan2024 | Oct2025 | Apr2026 | Sep2026 | Oct2026 |
|---|---|---|---|---|---|
Shares outstanding (millions) | 665 | 198.4 | 13.2 | 16.3 | 29.0 |
Valuation Multiples
| Multiple | Aprogen Biologics | Notes |
|---|---|---|
EV/EBITDA (x) | -7.25 | MarketInOut, Sep 2026; negative EBITDA |
EV/Sales (x) | 3.32 | MarketInOut, Sep 2026; before the September placement |
P/B (x) | 0.22 | Butler, Oct 2026 |
Capital Instruments
| Instrument | Amount (KRW Bn) | Coupon | Maturity | Holder |
|---|---|---|---|---|
16th-series CB | 40.0 | — | — | — |
17th-series CB | 65.0 | — | Not disclosed; to be refinanced in part by 18th series | — |
18th-series CB | 15.0 | 3% | 24 Oct 2030 | APTN |
19th-series CB | 10.0 | — | — | Aprogen Inc. |
Loan from Aprogen Inc. | 53.5 (early 2024) | — | — | Aprogen Inc. |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance and consensus
Aprogen Biologics guidance: none formally issued.
Group IR (June 2025): turnaround expected around 2027, driven by CDMO contracts, biosimilar licensing and novel drugs.
Consensus: none (no coverage).
Bull case
-
Regulatory catalyst. With FDA and EMA indicating that AP063 can be approved without confirmatory Phase 3, PPQ batches at Osong in 2026–2027 would convert the plant from idle to productive. Each AP063 batch is claimed at 92 kg.
-
Asset value versus market value. Market capitalisation of about KRW 42 bn compares with equity of KRW 272.8 bn (P/B 0.22) and a plant that cost about KRW 600 bn. Any contract that monetises the plant could re-rate the shares.
-
Diversified earnings floor. The pharmaceutical segment (profitable in Q1 2026) and the semiconductor segment (KRW 2.25 bn H1 operating profit) give a revenue base of about KRW 86 bn TTM that cushions bio losses.
Bear case
-
Funding treadmill. Losses of about KRW 60 bn a year at operating level and KRW 105–168 bn at net level are being funded by repeated parent and affiliate placements and CBs. The parent itself lost KRW 95.6 bn at operating level in FY2025.
-
Minority-shareholder dilution and governance. Two consolidations (2024 and 2026), a placement equal to 78% of the share count to the parent for an undetermined acquisition, and about KRW 81 bn of collateral for the parent's debt all signal that minority interests rank behind group needs.
-
Delisting and impairment. The KRX warning (October 2026) and a possible write-down of the KRW 152.8 bn machinery balance at year-end 2026 could trigger administrative-issue designation and further equity erosion before any biosimilar revenue arrives.
Key catalysts and monitorables (next 12 months)
-
Whether KRX designates the stock an administrative issue after the October 2026 warning, and whether the new shares listed in October lift market capitalisation above the threshold.
-
Identity of the target for the September 2026 KRW 20 bn acquisition funding, and the identity and repayment of the KRW 29.1 bn 아인스팩 loan.
-
AP063 PPQ start at Osong and US BLA / EU MAA submission dates.
-
First commercial CDMO contract announcement (value, client, duration).
-
FY2026 year-end impairment testing of Osong assets.
-
Release or extension of the Osong collateral pledged for Aprogen Inc.
-
Conversion activity on outstanding CBs and any new CB or placement.
-
Disclosure of the semiconductor segment's legal structure and outlook.
Analyst verdict
Aprogen Biologics is best understood as an option on the Aprogen group's biosimilar strategy, carried by a balance sheet that is being steadily drawn down. The underlying asset is real. Osong is a modern, certified, fully integrated antibody plant, and its perfusion process has produced clinical-scale batches at yields well above conventional fed-batch norms. The regulatory environment has also moved in the group's favour. FDA and EMA feedback that AP063 may not need a confirmatory Phase 3 is a meaningful de-risking step, and it shortens the path to commercial volumes.
The financial record, however, shows a business that has not yet earned its cost of capital at any point since the December 2022 merger. Operating losses have run at KRW 52.8–60.4 bn a year. Net losses reached KRW 168.3 bn in FY2025. Equity halved in about two and a half years, and the plant produced nothing in Q1 2026. The company has filled the gap through capital actions that dilute or subordinate outside shareholders. These include two share consolidations, repeated placements to the parent, CBs placed with affiliates, collateral pledged for the parent's debt, and a 78% share issuance for an acquisition the company itself says is undetermined. Because the parent is itself loss-making, the support network is circular rather than independent.
For investors, three conditions would need to hold for value to accrue to minority holders: AP063 PPQ and filings proceed on schedule; a bona fide third-party CDMO contract is signed; and governance practices around related-party funding improve. None is assured. Until at least two are visible, the shares should be treated as a high-risk, event-driven position, with listing-maintenance and dilution as the dominant near-term risks. On current evidence, the risk-reward is unfavourable for minority shareholders, and position sizing should reflect the possibility of administrative-issue designation and further capital actions in 2026–2027.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Education |
|---|---|---|---|
Kim Jeong-chool (김정출) | Co-CEO | Co-CEO since at least March 2023 (Asia Economy); also listed as CEO by Simply Wall St | — |
Kim Jae-seob (김재섭) | Co-CEO; also CEO of Aprogen Inc. and inside director of G-Base | Founder of Aprogen (2000); previously associate professor of biological sciences at KAIST, assistant professor at Seoul National University's Institute for Molecular Biology and Genetics, and research assistant professor at the University of Wisconsin; CEO of Schnell Biopharmaceuticals around 2013 | PhD, MSc and BSc in Microbiology, Seoul National University |
Lee Seung-ho (이승호) | Former co-CEO, head of bio division | — | — |
Na Oh-seong (나오성) | Managing Director, Osong Plant Head | Previously head of fill-finish at Aprogen Biologics; HA/DS team leader at Hanmi Pharmaceutical; culture-team supervisor and fill-finish team lead at Celltrion | MSc Chemistry, POSTECH; BSc Chemistry, Dongguk University |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake (%) | Date | Source |
|---|---|---|---|
Aprogen Inc. | 53.77 | Mar 2024 | Asia Economy |
Aprogen Inc. | 56.87 | 31 Mar 2025 | Aprogen IR (Jun 2025) |
Aprogen Inc. ("Aprogen Medicines Inc.") | 64.19 | 2026 (9,202,202 shares per Investing.com) | Investing.com |
Undisclosed buyer (acquired from Aprogen Inc.) | 6.87 | Jul 2024 | MarketScreener |
APTN (affiliate) | CB holder, KRW 15 bn 18th series; equity stake not disclosed | Oct 2025 | Dealsite |
Treasury shares | 0.53 | Oct 2026 | Butler |
Free float | 23.46 | 2025 | MarketScreener |
Competitive Landscape
Market Share by Competitor
| Company | Share of global CDMO market 2023 (%) |
|---|---|
Lonza | 25.6 |
WuXi Biologics | 12.1 |
Catalent | 10.1 |
Samsung Biologics | 9.9 |
Fujifilm | 6.8 |
Boehringer Ingelheim | 5.9 |
AGC Biologics | 4.4 |
Others | 25.2 |
Key Competitors
| Company | Installed volume (thousand L) | Process |
|---|---|---|
Samsung Biologics | 604 | Fed-batch (Plants 1–4) |
Celltrion | 250 | Fed-batch (Plants 1–3) |
Aprogen Biologics (actual) | 10.5 | Perfusion |
Aprogen Biologics (company-claimed fed-batch equivalent) | 360 | Conversion claimed by Aprogen |
Peer Comparison FY2025
| Metric | Aprogen Biologics | Celltrion | Samsung Biologics | Prestige BioLogics |
|---|---|---|---|---|
Revenue (KRW Bn) | 73.2 | 4,162.5 | 4,557.0 | 12.5 |
Revenue growth YoY (%) | 8.6 | 17.0 | 30.3 | — |
Operating income (KRW Bn) | -60.4 | 1,168.5 | 2,069.2 | — |
Operating margin (%) | -82.5 | 28.1 | 45.4 | — |
Recent Developments
Not identified in sources reviewed: * layoffs, product launches, contract wins, and litigation events. The TheVC headcount series (146 in June 2026, down 6% month-on-month) suggests ongoing attrition.



